5 things to read instead of… BCC fail
The email BCC can be a tricky beast to work with. As Theranos found out this week, a conversation can seem so secure, until it isn’t. Continuing their investigation into the embattled blood-testing company, The Wall Street Journal have revealed a long list of the company’s investors whose names came to light when Theranos failed to conceal their names behind a BCC barrier. I’m sure we all have our fair share of email fails, but let’s just be glad that they weren’t that severe!
MIT Technology Review‘s Emily Mullin takes a look at a small clinical trial of an experimental vaccine for acute myeloid leukemia, where the majority of patients are now in remission. The vaccine, administered after an initial round of chemotherapy, was designed to “reeducate” the body’s immune cells to see cancer cells as foreign, and attack them.
Luke Timmerman takes a look at some of the young entrepreneurs making their way in biotech, and challenging the venture capital preference for lining up “behind people with gray hair in there 40s, 50s, and 60s.”
This strongly-worded op-ed in the National Review caught my eye this week, and it’s one I would love to get the FLG audience take on! Julie Kelly argues that scientists should steer clear of expressing political opinions publicly, arguing that it compromises their scientific objectivity. Her comments come in the wake of many vocal concerns over the impact that the incoming Trump administration will have on the scientific community.
The Signal podacast is one year old this week, and over the course of the year they have covered some fantastic scientific topics. Looking back over the course of the year, hosts Like Timmerman and Meg Tirrell look back at just how far the field of science can come in a single year.
And one from us…
Three naturally occurring proteins could be used to put the brakes on CRISPR/Cas9 gene-editing, acting as an “off-switch” for any unwanted or excessive genetic changes. According to the study, published in Cell these proteins, known as anti-CRISPRs, have the ability to block DNA cleavage by the Cas9 nuclease.